Study shows that selection of breast cancer patients for adj

Study shows that selection of breast cancer patients for adjuvant bisphosphonate therapy based on Inbiomotion's MAFTEST reduces the risk of death in comparison with current clinical guidance

MAFTEST analyses of the NSABP-B34 and AZURE landmark clinical trials confirmed clinical utility of the MAFTEST for selection of early-stage breast cancer patients that benefit from adjuvant

Related Keywords

Barcelona , Comunidad Autonoma De Cataluna , Spain , United Kingdom , Rogerr Gomis , Robert Coleman , Roger Gomis , Alexander Hg Paterson , Alexander Paterson , Research Professor , University Of Calgary , Department Of Oncology , University Of Sheffield , Professor Emeritus , Emeritus Clinical Professor , Executive Chairman , Study , Shows , Election , Breast , Dancer , Patients , Adjuvant , Bisphosphonate , Therapy , Ased , Inbiomotion , Faftest , Educes , Risk , Death , Comparison , Current , Linical , Guidance ,